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An abdominal aortic aneurysm (AAA) is defined as a permanent dilation of the abdominal aorta by >50% 
or >3 cm and occurs in up to 8.00% of men over the age of 
65 years and between 0.37% and 1.53% of women over the 
age of 60 years.1,2 Complications of AAAs, such as rup-
ture or dissection, have an associated mortality of >80%.3 
Inflammation is of major importance in aneurysm forma-
tion and progression.1,4,5 Patients with an AAA display 
increased serum concentrations of interleukin-1β, TNF 
(tumor necrosis factor) α, CCL2 (chemokine [C-C motif] 
ligand 2), interleukin-6, and interferon γ (IFNγ) while 
several inflammatory mediators affect AAA development 
in mice.6–9 Similarly, expression levels of matrix metallo-
proteinase (MMP) 9 are increased in human AAA tissue, 
and levels of tissue inhibitor of metalloproteinase-2 are 
decreased.10
A TNF-related signaling pathway implicated in inflam-
mation and matrix turnover is the CD40-CD40L dyad.11 
In atherosclerosis, inhibition of CD40-CD40L signaling 
decreases plaque size and results in a plaque phenotype 
that contains high amounts of fibrosis and low amounts 
of inflammation, reminiscent of a stable plaque.12–15 Here, 
we investigate the role of CD40L in AAA development in 
humans and mice.
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Objective—The mechanisms underlying formation of arterial aneurysms remain incompletely understood. Because 
inflammation is a common feature during the progressive degeneration of the aortic wall, we studied the role of the 
costimulatory molecule CD40L, a major driver of inflammation, in aneurysm formation.
Approach and Results—Transcriptomics data obtained from human abdominal aortic aneurysms and normal aortas revealed 
increased abundance of both CD40L and CD40 in media of thrombus-free and thrombus-covered human abdominal aortic 
aneurysms samples. To further unravel the role of CD40L in aneurysm formation, apolipoprotein E–deficient (Apoe−/−) and 
Cd40l−/−Apoe−/− mice were infused with angiotensin II for 7 and 28 days. Only a minority of Cd40l−/−Apoe−/− mice (33% and 
17%) developed (dissecting) aneurysms compared with 75% and 67% of Apoe−/− littermates after 7 and 28 days of infusion, 
respectively. Total vessel area of the aorta at the suprarenal level was 52% smaller in angiotensin II–infused Cd40l−/−Apoe−/− 
mice compared with that in angiotensin II–infused Apoe−/− mice. Chimeric Apoe−/− mice repopulated with Cd40l−/−Apoe−/− bone 
marrow afforded a similar protection against dissecting aneurysm formation. Moreover, lack of CD40L protected mice from fatal 
aneurysm rupture. T helper cell and macrophage accumulation in aneurysmal tissue was reduced in Cd40l−/−Apoe−/− mice with a 
concomitant decrease in expression of proinflammatory chemo- and cytokines. In addition, aneurysms of Cd40l−/−Apoe−/− mice 
displayed reduced abundance of matrix metalloproteinase-13 and an increase in tissue inhibitor of metalloproteinase-3 while 
activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 was diminished.
Conclusions—Deficiency of (hematopoietic) CD40L protects against dissecting aneurysm formation and reduces the 
incidence of fatal rupture. This is associated with a decreased accumulation and activation of inflammatory cells and a 
dampened protease activity in the arterial wall.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38: 
1076-1085. DOI: 10.1161/ATVBAHA.117.310640.)
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Materials and Methods
Microarray
Patient samples were obtained from elective open surgery for AAA 
treatment and control samples from the abdominal aorta of solid organ 
transplant donors. A total of 76 samples were obtained from AAA with 
thrombus-covered vessel wall, 34 from AAA with thrombus-free vessel 
wall, and 13 samples from the abdominal aortas of solid organ trans-
plant donors. The elective open aortic repair surgeries were performed 
between 2009 and 2016, the solid organ transplant surgeries in 2014, 
both at the Karolinska University Hospital in Stockholm, Sweden. The 
samples were immediately immersed in RNA stabilization solution 
(RNAlater, Thermo Fisher Scientific, Waltham, MA), separated into 
intima/medial and adventitial wall layers, and then stored in −80°C. RNA 
was isolated using Qiazol Lysis Reagent (Qiagen) and purified using 
the RNeasy minikit (Qiagen). The concentration of RNA was measured 
using Nanodrop ND 1000 (Thermo Fisher Scientific). Gene expres-
sion was analyzed with Affymetrix HTA 2.0 Genechip arrays (Thermo 
Fisher Scientific). Raw CEL intensity files were normalized through 
Guanine Cytosine Count Normalization, Signal Space Transformation, 
and Robust Multi-array Average by use of the Affymetrix Expression 
Console software (Thermo Fisher Scientific). The Bioconductor tool 
limma16 was used in R17 to determine differential gene expression, with 
the empirical Bayes moderation of standard errors for the microarray 
linear model. The study was approved by the Regional Ethical Review 
Board in Stockholm (Dnr 2009/9–31/4, Dnr 2013/615–31/:4).
Mice
Cd40l−/− apolipoprotein E–deficient (Apoe−/−) and Apoe−/− mice on 
a C57BL/6 background were bred in our animal facility. More than 
10 backcrosses with Apoe−/− mice were performed to obtain double 
knockout mice. Mice were fed a normal laboratory diet throughout 
the experiment. At 10 weeks of age, Alzet osmotic minipumps (Model 
2004; Durect Corporation, Cupertino, CA), containing angiotensin 
II (AngII; Sigma A9525), were implanted subcutaneously into both 
Apoe−/− (n=27) and Cd40l−/−Apoe−/− mice (n=26). AngII was infused at 
a rate of 1000 ng/kg per minute for 28 days or 7 days in Apoe−/− (n=7) or 
Cd40l−/−Apoe−/− (n=15).18 At the end of the experimental period, mice 
were euthanized after 4 hours of fasting. Blood was collected from the 
right ventricle for plasma cholesterol concentrations. The presence of 
macroscopic dissecting aneurysm and rupture was noted.
Mice were randomly divided into 2 groups. One group was used 
for histological and morphometric analysis (28 days: Apoe−/−: n=12 
and Cd40l−/−Apoe−/−: n=10, 7 days: Apoe−/−: n=5 and Cd40l−/−Apoe−/−: 
n=6) and a second group for mRNA and protein analyses (Apoe−/−: 
n=16 and Cd40l−/−Apoe−/−: n=15, 7 days: Apoe−/−: n=6 and Cd40l−/−
Apoe−/−: n=13). All animal experiments were performed under 
approved institutional animal care of the respective universities.
Bone Marrow Transplantation
Apoe−/− mice (n=20) were lethally irradiated (10 Gy, 0.5 Gy/min; 
MU 15F/225 kV; Philips) and injected intravenously with 5×106 bone 
marrow–derived cells from Apoe−/− and Cd40l−/−Apoe−/− mice.13 Mice 
were maintained in filter-top cages and given water containing 60 000 
U/L polymyxin B sulfate and 100 mg/L neomycin (both Invitrogen) 
from 1 week before bone marrow transplantation until 4 weeks after-
ward. Six weeks after transplantation, osmotic minipumps were 
inserted subcutaneously into both the Apoe−/− and Cd40l−/−Apoe−/− 
mice. AngII was infused at a rate of 1000 ng/kg per minute. Mice 
were euthanized after 28 days of infusion.
Histological Analyses
For morphometric analyses, the entire arterial tree was perfused with 
PBS containing 0.1 mg/mL sodium nitroprusside dihydrate (Sigma), 
followed by 1% paraformaldehyde via a catheter inserted into the 
left ventricle. The arterial tree was excised and fixed overnight in 1% 
paraformaldehyde and embedded in paraffin. Cross-sections (4 μm) of 
the suprarenal area of the abdominal aorta (with or without dissecting 
aneurysms) were obtained at 12 different levels at 200 μm intervals. 
Cross-sections from each level were stained with hematoxylin and 
eosin and Elastica von Gieson. Total vessel area on all 12 levels was 
measured on a Leica DM6000 Light microscope (Leica Microsystems) 
coupled to a computerized morphometry system (Leica Qwin 3.5.1).
Immunohistochemistry
To characterize accumulation of inflammatory cells in aneurismal tis-
sue and the surrounding tissue, cross-sections were immunostained 
with anti–MAC-3 (BD Lifescience) for presence of macrophages, 
anti-CD45 (Becton & Dickenson) for leukocyte infiltration, and anti-
CD3 (Dako) for T cell infiltration, anti-B220(1D3) for B cell infiltra-
tion, anti-CD4(RM4-5), or anti-CD8(5H10), kindly provided by Dr 
Duijvestijn. MAC-3, CD45, and CD3 immunostainings were quan-
tified using a scoring system where no chromogen yielded a score 
of 0 and maximum color corresponded to a score of 5. Scoring was 
performed by 1 investigator blinded to the identity of the sections. 
The intraobserver variability was <10%.
RNA and Protein Analyses
Abdominal aortas of mice were excised for RNA or protein analyses 
and immediately snap frozen in liquid nitrogen and stored at −80°C 
until further use. The presence of a macroscopic visible aneurysm 
was documented.
RNA Isolation and Quantitative Real-
Time Polymerase Chain Reaction
Aortic tissues were homogenized, and RNA was isolated using the 
Qiagen RNeasy mini kit (Qiagen). For the preparation of cDNA, 
the iScriptcDNA Synthesis Kit (Bio-Rad) was used according to 
manufacturer’s protocols. Quantitative polymerase chain reaction 
was performed using the SYBR Green method. A total of 10 ng of 
cDNA was used with the 2× quantitative polymerase chain reaction 
master mix (Bio-Rad). Expression of matrix metalloproteinases and 
their inhibitor genes pro- and anti-inflammatory genes and the regu-
latory T cell–specific gene Foxp3 were analyzed. Finally, CD40 and 
CD40L expression were analyzed. The reference genes cyclophilin A 
and β-actin were used to normalize RNA abundance.
Gelatin Zymography
MMP-2 and MMP-9 activities were determined in aortic/aneurysm 
tissues of Apoe−/− and Cd40l−/−Apoe−/− mice. Tissue samples were 
extracted in 150 µL sodium dodecyl sulfate lysis (10% glycerol, 20% 
sodium dodecyl sulfate, 10% 1.5 mol/L Tris pH 6.8) buffer by cut-
ting the tissue into small pieces after which total protein concentra-
tion was adjusted to 75 μg. Murine vascular smooth muscle cells 
incubated with TNF-α+platelet-derived growth factor was used as a 
control. MMP-2 and MMP-9 activities in extracts were detected as 
described previously.19 Briefly, 4 µL of tissue extract was diluted (1:5) 
with distilled water. Samples were electrophoresed in the presence of 
nonreducing buffer at 4°C in 7.5% sodium dodecyl sulfate polyacryl-
amide gels containing 2 mg/mL gelatin. After the removal of sodium 
dodecyl sulfate, gelatinase activity was revealed by overnight incuba-
tion at 37°C and subsequent staining with 0.1% Coomassie brilliant 
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blue. Zymograms were quantified in the linear range by densitometry 
with Quantity One 1-D Image Analysis software system (Bio-Rad).
Lipid Analyses
Plasma cholesterol concentrations were measured using an enzymatic 
assay (Roche).
Statistical Analyses
Data are expressed as mean±SEM. The Mann–Whitney nonparamet-
ric test was used to compare the Cd40l−/−Apoe−/− and Apoe−/− groups. 
When analyzing incidence of aneurysm formation and incidence of 
death before end of the experiment, the Fisher exact test was used. 
Kaplan–Meier survival curves were analyzed using log-rank (Mantel–
Cox) test. Flow cytometry data were analyzed using Student t test. Data 
with probability values <0.05 were considered statistically significant.
Results
Increased Expression of CD40L and CD40  
in Human AAA
Microarray data from the Stockholm AAA Biobank were used 
to study the expression levels of CD40L and CD40 mRNA in 
human AAA disease. Tissue samples of thrombus-free (n=34) 
and thrombus-covered (n=76) AAA wall segments, collected 
from open aortic repair conducted between the years 2009 and 
2016, as well as tissue samples of nonaneurysmal abdominal 
aorta (n=13), obtained from solid organ transplant surgeries 
performed in 2014, were immersed immediately in RNA sta-
bilization solution and then separated into intima/medial and 
adventitial layers. Microarray-based gene expression analy-
ses of these samples revealed overexpression of both CD40 
and CD40L in the thrombus-free and thrombus-covered AAA 
aortic media compared with control aortic media (Figure 1). 
In mice, CD40L expression was also increased in the abdomi-
nal aorta when comparing Apoe−/− mice who did not receive 
AngII infusion to mice receiving AngII for 7 days (relative 
expression±SEM 0 versus 7 versus 28 days Ang II=0 days: 
1.00±0.37 versus 7 days: 2.12±0.15 versus 28 days: 1.04±0.60).
CD40L Deficiency Protects Against AngII-Induced 
Dissecting Aneurysm Formation in Apoe−/− Mice
After 28 days of AngII infusion, the incidence of mature 
aneurysms (characterized by extensive dilatation±dissection 
and or hemorrhage) was only 17% in Cd40l−/−Apoe−/− mice 
compared with 67% in Apoe−/− mice (Figure 2A). Overall 
survival was not significantly different between groups 
(Figure 2B). The protective effect of CD40L deficiency was 
reflected in a 52% smaller total vessel area in Cd40l−/−Apoe−/− 
mice (Figure 2C and 2D). However, once a dissecting aneu-
rysm had developed in Cd40l−/−Apoe−/− mice, no differences 
in aneurysm area were found compared with Apoe−/− mice 
that had developed a dissecting aneurysm (Figure 2E). No 
changes in body weight or plasma cholesterol concentrations 
were observed (Figure I in the online-only Data Supplement).
After 28 days of AngII infusion, lack of CD40L led to signifi-
cantly lower abundance of CD45+, CD4+, and Mac3+ leukocytes in 
the abdominal vascular wall, whereas the number of B220+ B cells 
and CD8+ T cells was not significantly affected (Figure 2F–2L). 
Moreover, abdominal aortas of AngII-treated Cd40l−/−Apoe−/− 
mice exhibited reduced transcription of the chemokines CCL2 
and CCL3 (Figure 3A) and the cytokine interleukin-12 with a 
trend toward lower IFNγ (P=0.05; Figure 3B) when compared 
with AngII-treated Apoe−/− mice. CD40 transcript levels did not 
change while CD40L levels could barely be detected in abdomi-
nal aortas of Cd40l−/−Apoe−/− mice (Figure 3C and 3D).
Furthermore, when Cd40l−/−Apoe−/− bone marrow was 
transplanted into lethally irradiated Apoe−/− mice, the incidence 
of dissecting aneurysm formation in Cd40l−/−Apoe−/− chi-
meras was significantly reduced (30% in Cd40l−/−Apoe−/− 
chimeras versus 63% in Apoe−/− chimeras). In addition, 
Figure 1. CD40L and CD40 are overexpressed in human aortic abdominal aneurysm (AAA) media. Microarray on CD40 and CD40L, 
thrombus-free (n=34) and thrombus-covered (n=76) human AAA samples obtained from elective surgery were compared with control 
thrombus-free samples (n=13). ns indicates nonsignificance. *P<0.05, ****P<0.0001.
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Figure 2. CD40L deficiency reduces dissecting aneurysm formation. Male Cd40l−/− apolipoprotein E–deficient (Apoe−/−) and Apoe−/− 
mice were infused with angiotensin II (AngII) via minipumps and analyzed after 7 or 28 d. A, Incidence of aneurysms at 7 d and at 28 
d. B, Survival curves. C, Representative photomicrographs of Elastin-van-Giesson staining of a normal aorta (left) in a nonresponding 
Cd40l−/−Apoe−/− mouse and advanced dissecting aneurysm in an Apoe−/− (middle) and Cd40l−/−Apoe−/− mouse (right) after 28 d of AngII 
infusion. D, Total vessel area and (E) aneurysmal area of the abdominal aorta of Apoe−/− and Cd40l−/−Apoe−/− mice. F–L, Immunohisto-
chemical analysis of immune cell infiltrate in aneurysmal tissue of Apoe−/− and Cd40l−/−Apoe−/− mice. Semiquantitative analysis of (F) 
CD45+ cells with (G) representative photomicrographs and (H) Mac3+ cells with (I) representative photomicrographs after 28 d of infu-
sion (arrows indicate areas of positive staining). Semiquantitative analysis of (J) CD4+, (K) CD8+, and (L) B220+ cells after 7 and 28 d of 
infusion. *P<0.05; scale bar depicted in μm.
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Figure 3. CD40L deficiency limits inflammation and proteolytic activity in dissecting aneurysms. Male Cd40l−/− apolipoprotein E–deficient 
(Apoe−/−) and Apoe−/− mice were infused with angiotensin II–releasing minipumps and analyzed after 7 or 28 d. Quantitative polymerase 
chain reaction (Q-PCR) of chemokines after (A) 7 and 28 d of infusion, (B) cytokines after 7 and 28 d of infusion. C and D, Q-PCR of CD40 
and CD40L levels. E, Q-PCR of matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) after 7 or 28 d. F and G, 
Quantification of MMP activity by gelatin zymography. Vascular smooth muscle cells, incubated with TNF (tumor necrosis factor) α and 
platelet-derived growth factor, were used as positive control. Samples were abdominal aortic tissue from Apoe−/− and Cd40l−/−Apoe−/− 
mice (d28). F, Representative zymogram and (G) quantification of MMP activity of Apoe−/− and Cd40l−/−Apoe−/− mice (*P<0.05; **P<0.01). 
AU indicates arbitrary units.
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Cd40l−/−Apoe−/− chimeras were protected from death by 
aneurysm rupture indicating a strong contribution of hema-
topoietic CD40L in the pathogenesis of aneurysm formation 
(Figure IIIA and IIIB in the online-only Data Supplement).
CD40L Deficiency Reduces Proteolytic Activity
Paralleling the decrease in inflammation, absence of CD40L 
significantly reduced indicators of proteolytic activity. After 
28 days of AngII infusion, MMP-13 mRNA levels were 
decreased, whereas tissue inhibitor of metalloproteinase-3 
mRNA abundance increased in the abdominal aorta of Cd40l−/− 
Apoe−/− mice compared with Apoe−/− controls (Figure 3E). 
Moreover, gelatin zymography revealed a significant decrease 
in both MMP-2 and MMP-9 activity, as well as pro–MMP-9 
accumulation in abdominal aortas of Cd40l−/−Apoe−/− mice, 
suggesting an intrinsic protection against dissecting aneu-
rysm formation in the arterial wall of Cd40l−/−Apoe−/− mice 
(Figure 3F and 3G). No differences in the incidence of elastin 
breaks or the amount of collagen in the media of the abdomi-
nal aorta were observed between groups (Figure 4A–4F).
CD40L Deficiency Is Protective in 
Early Aneurysm Development
To identify processes preceding mature aneurysm forma-
tion, mice were analyzed after only 1 week of AngII infusion. 
Initial signs of aneurysm formation (visible dilatation, vas-
cular hematomas) were present in a large portion of Apoe−/− 
mice after 7 days of infusions, with a lower incidence in the 
Figure 4. CD40L deficiency does not affect incidence of elastin breaks or collagen abundance. Male Cd40l−/− apolipoprotein E–deficient 
(Apoe−/−) and Apoe−/− mice were infused with angiotensin II via minipumps and analyzed after 28 d. A, Mean incidence of elastin breaks 
on Elastica von Gieson (EVG) staining per section in aneurysms. B, Semiquantitative analysis of collagen content on Sirius red staining 
in Apoe−/− and Cd40l−/−Apoe−/− mice after 28 d. Representative images of aneurysms from (C) Apoe−/− mice and (D) Cd40l−/−Apoe−/− mice 
depicting elastin breaks (indicated by arrows; scale bar=100 µm) and from Sirius red staining in (E) Apoe−/− and (F) Cd40l−/−Apoe−/− mice 
(scale bar=200 µm).
1082  Arterioscler Thromb Vasc Biol  May 2018
Cd40l−/−Apoe−/− group (P=0.05; Figure 2A). Furthermore, 
CD40L deficiency reduced the abundance of inflammatory 
cells, in particular of CD4+ T cells, in the abdominal aorta, 
whereas the accumulation of B220+ B cells was not affected 
(Figure 2J–2L). Moreover, in absence of CD40L, abdominal 
aortas showed a decrease in CCL2, CCL12, CCL3, CXCL2 
(chemokine [C-X-C motif] ligand 2), and CCL5, and TNFα 
transcript abundance suggesting that absence of CD40L 
ameliorates inflammatory responses in the initial stages of 
aneurysm formation (Figure 3A and 3B). Accordingly, flow 
cytometric analysis of spleen and blood revealed a decrease 
in CD11b+, Ly6G+, Ly6Chigh cells as well as CD4+ and CD8+ 
effector cells in Cd40l−/−Apoe−/− mice (Figure 5; Figure III in 
the online-only Data Supplement).
The fraction of CD4+FoxP3+ regulatory T cells was also 
decreased (Figure 5F). However, this can be explained by 
a negative effect of inhibiting CD40-CD40L on regulatory 
T cells via interleukin-2–mediated decreased regulatory T 
cell expansion and survival after dendritic cell encounter as 
described previously.20
Figure 5. Reduced effector T cells and Foxp3+ regulatory T cells after 7 d. Flow cytometric analysis of spleens from apolipoprotein E–defi-
cient (Apoe−/−) and Cd40l−/−Apoe−/− mice after 7 or 28 d of infusion. A, CD3+ cells, (B) CD4+ T helper cells, (C) CD8+ cytotoxic T cells, (D) 
effector CD4+ T cells, (E) effector CD8+ cells, (F) Foxp3+ regulatory T cells, (G) CD11b+ cells, and (H) Ly6Chi monocytes. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001.
Kusters et al  The Role of CD40L in Aneurysm Formation  1083
Discussion
Here, we show that CD40L deficiency strongly reduces the 
incidence of dissecting aneurysms by limiting inflamma-
tion and extracellular matrix degradation in the arterial wall. 
However, once a dissecting aneurysm develops, CD40L defi-
ciency cannot prevent the progression as shown by similar 
sizes of developed aneurysms.
We found that CD40L deficiency especially dampened Th1 
(T helper 1)-related cytokines in aneurysms and that production 
of these cytokines via CD40-CD40L signaling is imperative in 
dissecting aneurysm formation. This observation is in agreement 
with an AAA-eliciting role of the hallmark Th1 cytokines IFNγ 
and TNFα as reported before.21,22 However, there is still debate 
and contradiction whether AAA is promoted by Th1-, Th2-, or 
Th17-dominated cytokine responses, and multiple reports have 
conflicting outcomes.4,6,23 Xiong et al22 showed a pivotal role for 
TNFα in calcium chloride–induced AAAs, whereas Shimizu 
et al24 showed that allograft AAAs were increased in IFNγ-
deficient mice and harbored a Th2-skewed cytokine environ-
ment. Zhou et al25 found a pathogenic role for IFNγ-producing 
CD8+ T cells and found that IFNγ antagonism prevents disease 
in wild-type mice in an elastase-infusion model. However, King 
et al26 observed greatly increased aneurysm severity in AngII-
induced dissecting aneurysms in IFNγ−/− mice. Yet, in mice 
lacking CD40L, we observed a decrease in TNFα at day 7, as 
well as IFNγ, and interleukin-12 28 days postaneurysm initia-
tion, respectively. These findings are in accordance with previ-
ous studies underlining the importance of Th1 cytokines and 
reflect the complex role of cytokines in aneurysm pathophysi-
ology. Indeed, different cytokines, chemokines, and proteases 
seem affected by CD40L at different time points in the disease 
process. The significant decrease in the inflammatory subsets of 
T cells and monocytes in Cd40l−/−Apoe−/− mice, combined with 
the aforementioned decrease in proinflammatory cytokines 
and chemokines, points toward a generalized reduction in the 
inflammatory status of these mice. This is in accordance with 
the strong proinflammatory effects of CD40-CD40L signaling 
in other disease models.11,17
Another cytokine/growth factor imperative for AAA devel-
opment is TGFβ (transforming growth factor beta).27 However, 
the specific role is controversial. Notably, TGFβ abundance is 
increased in AAA vascular tissue, both in syndromic diseases, 
such as Marfan, as well as nonsyndromic disease.28 TGFβ activ-
ity was recently ascribed a protective function against AAA 
formation, in particular via a key component of the canonical 
TGFβ signaling pathway, SMAD3.7,29 We observed a mod-
est decrease in TGFβ levels after 7 days but no change after 
28 days in CD40L deficiency, suggesting that CD40L mostly 
drives inflammation during disease initiation. Discrepancies in 
study results may derive from different models used to induce 
AAA with diverging pathophysiological mechanisms.30
Modulation of MMP activity and other proteolytic medi-
ators is an important mechanism in reducing the incidence of 
AAA.31 Mice deficient in MMP-2, MMP-3, and -9 displayed 
fewer AAAs.32,33 CD40L is a potent inducer of MMP activa-
tion.11 Accordingly, CD40L deficiency resulted in decreased 
MMP-2 and -9 activity and MMP-13 mRNA abundance 
in AAA tissue. Interestingly, we found that the effects on 
inflammation preceded effects on proteolysis as shown in 
the difference between findings after 7 and 28 days. This 
indicates an early effect of CD40L on inflammation in the 
formation of dissecting aneurysms while at later time points, 
proteolysis and extracellular matrix degradation seem 
affected by CD40L in AngII-induced dissecting aneurysms.
Although this study is the first to examine the effects of 
CD40-CD40L signaling on aneurysm formation in a gene-defi-
cient model, previous studies have investigated CD40-CD40L 
as a potential biomarker or therapeutic target. The antiplatelet 
drug trapidil, which inhibits CD40-CD40L, among other func-
tions, when used on tissue from human AAA patients, inhib-
its MMP-2 but not MMP-9.34 Interestingly, an anti-CD40L 
monoclonal antibody also only selectively blocked MMP-2.34 
In the present study, we found a significant decrease of only 
MMP-13 mRNA levels although we noticed decreased activ-
ity of MMP-2 and (pro)MMP-9 by gelatin zymography.
Thus far, no correlation of (s)CD40L levels with AAA 
incidence have been reported.35,36 However, concentrations 
of sCD40L, mainly secreted by platelets, are not necessarily 
related to local CD40-CD40L activity nor rule out a function 
of CD40-CD40L signaling in disease pathology, as also seen by 
conflicting data on sCD40L as a biomarker for cardiovascular 
disease, despite a proven role of CD40-CD40L in atherosclero-
sis.17 Furthermore, when measured inside the luminal thrombus 
layer from patients with AAA in a separate study, sCD40L lev-
els were increased compared with other layers.37 In addition, 
plasma levels of sCD40L were increased in patients compared 
with controls underlining a potential role for CD40L in human 
disease and reflecting the results of our study.37 We now show 
that indeed, transcript levels of CD40 and CD40L are increased 
in the arterial media of human thrombus-free or thrombus-cov-
ered AAA compared with nonaneurysmal control vessels.
Lack of CD40L mitigated dissecting aneurysmal disease both 
in a full gene-deficient as well as in a bone marrow transplant 
model, suggesting that CD40L on hematopoietic cells is a major 
contributor to the pathogenesis of dissecting aneurysm formation. 
However, a role of CD40L on nonhematopoietic cells cannot be 
ruled out. Moreover, as of now, it is unclear on which cell types 
CD40L exerts its effects or which signaling pathways are respon-
sible for these effects of CD40L. Further studies using cell-spe-
cific gene-deficient models and inhibition of specific parts of the 
CD40-CD40L signaling cascade will further elucidate the func-
tion of this potent costimulatory molecule pair in vascular disease, 
including AAA, and potentially direct new therapeutic strategies.
To date, therapeutic options preventing growth or rupture 
of AAA are limited, and surgical interventions remain chal-
lenging, especially in the elderly. Therefore, novel pharmaco-
logical strategies are an unmet medical need in patients. Our 
data reveal that blocking CD40L protects the arterial wall from 
dissecting aneurysm formation by reducing the proteolytic 
profile, preceded by reduced inflammation. This protection is 
associated with lower risk of rupture. Thus, therapies inhibiting 
CD40L or downstream targets in the CD40-CD40L pathway 
may pose an attractive option for the stabilization of AAAs.
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Highlights
• The high morbidity and mortality associated with abdominal aortic aneurysm and the lack of efficient pharmacological intervention strategies 
emphasize the need to invest in novel therapies.
• CD40L is a key component in dissecting aneurysm pathogenesis by promoting (Th1 driven) inflammation and extracellular matrix degradation.
• Inhibition of CD40L is an attractive novel drug target for the stabilization of abdominal aortic aneurysm.
